BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dong-A Pharmaceutical Co., Ltd. Acquisition Of European COS Of An Active Anticancer Ingredient


1/24/2007 10:46:49 AM

SEOUL, South Korea, Jan. 24 /PRNewswire/ -- As the 1st leading company, Dong-A Pharmaceutical Co., Ltd. (Representative Mr. Won-Bae Kim) announced that Dong-A Pharmaceutical has been granted a COS(Certificate of Suitability of Monographs of the European Pharmacopoeia) for Epirubicin Hydrochloride, which is an active anticancer ingredient approved by the European directorate for the Quality of Medicines (EDQM).

The action mechanism helps Epirubicin HCL bind to DNA to inhibit the nucleic acid synthesis.

As the second generation anticancer ingredient which improved the side effects of the first generation anticancer ingredient, Doxorubicin, it is broadly used to treat some kinds of breast, stomach and lung cancers.

Also, COS(Certification of Suitability of Monographs of the European Pharmacopoeia) is a certificate that certifies the compliance of a material with the requirements laid down in the relevant monograph of the European Pharmacopoeia.

Dong-A Pharmaceutical Co., Ltd. expects that it is planning to enter into the European market with this COS of Epirubicin HCL and also its total sale will be more than 30 million dollars in global markets such as Latin America, India, and Australia.

Contact : Seong-Yeol Lee Assistant Manager ETC Export Dept. International Business Div. Phone : +82 2 920 8368 HP : +82 19 493 5711 Fax : +82 2 924 2662 e-Mail : esy@donga.co.kr Internet: www.donga.co.kr

Dong-A Pharmaceutical Co., Ltd.

CONTACT: Seong-Yeol Lee, Assistant Manager, ETC Export Dept.,International Business Div., Phone - +82-2-920-8368, HP - +82-19-493-5711,Fax - +82-2-924-2662, esy@donga.co.kr



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES